Investor Presentaiton

Complete Response Extracranial CR Not Evaluable (off treatment) In Evaluation Window Efficacy Results 4 of 14 (29%) Evaluable Patients had Disease Control (1 CR + 2 PR + 1 SD) 4 of 13 (31%) above minimum clinically effective dose of rigosertib had Disease Control Subject 19 G12A Partial Response Stable Disease 18 G12V 17 G13C/STK11 16 G13D 15 G12F/STK11 14 Q61H/STK11 13 Q12D 12 G12V 560 mg BID 11 G12D 10 G12V 6 G12D 8 G12V 7 G12D 6 G12D GU Toxicity (GR 2) 5 G12V 4 G12V GU Toxicity (GR 2) 3 G12V Hyponatremia (DLT) 560 mg/280 mg 2 G12C/STK11 10 280 mg BID 1 146T/STK11 0 1 2 3 4 5 6 7 8 9 10 Months Adapted from Veluswamy et al. European Society for Medical Oncology Congress 2022. DLT: Dose limiting toxicity; CNS: Central nervous system Progressive Disease Continues on Treatment Disease Progression CNS Metastasis Best Overall Response in Evaluable Patients (N=14) Complete Response (CR) 1 (7%) Partial Response (PR) 2 (14%) Stable Disease (SD) 1 (7%) Mean Duration of Response = 6.75 months Mean Duration of Extracranial Response = TBD ONCONOVA THERAPEUTICS

View entire presentation